Publications

1. Package advice for entrectinib and larotrectinib (Rozlytrek® and Vitrakvi®) for the treatment of adult and paediatric patients with solid tumours (cancer) with NTRK gene fusion

   The National Health Care Institute has assessed whether the medicinal products entrectinib and larotrectinib (Rozlytrek® and ...

   Report | 27-07-2023

2. GVS advice potassium citrate and potassium hydrogen carbonate (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

   The National Health Care Institute has assessed whether the combination preparation potassium citrate and potassium hydrogen ...

   Report | 19-07-2023

3. Additional GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

   The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

   Report | 13-07-2023

4. GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

   The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

   Report | 11-07-2023

5. Package advice on the lock procedure medicinal product lenvatinib (Lenvima®) for the treatment of endometrial carcinoma

   The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

   Report | 06-07-2023

6. GVS advice avacopan (Tavneos®) for the treatment of certain patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

   The National Health Care Institute has assessed whether avacopan (Tavneos®) can be included in the Medicine Reimbursement System ...

   Report | 15-06-2023

7. GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults

   The National Health Care Institute has assessed whether the hepatitis B vaccine PreHevbri® can be included in the Medicine ...

   Report | 02-06-2023

8. GVS advice lasmiditan (Rayvow®) for the treatment of migraine

   The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System ...

   Report | 23-05-2023

9. Advice on the clustering of combination products and ghost clusters in GVS (part 4)

   The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

   Report | 23-05-2023

10. Advice on the clustering of combination products and ghost clusters in GVS (part 3)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023